By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news reporting originating in Sassari, Italy, by NewsRx journalists, research stated, "Recent advances in nanotechnology and biotechnology have contributed to the development of engineered nanoscale materials as innovative prototypes to be used for biomedical applications and optimized therapy. Due to their unique features, including a large surface area, structural properties, and a long circulation time in blood compared with small molecules, a plethora of nanomaterials has been developed, with the potential to revolutionize the diagnosis and treatment of several diseases, in particular by improving the sensitivity and recognition ability of imaging contrast agents and by selectively directing bioactive agents to biological targets."
The news reporters obtained a quote from the research from the University of Sassari, "Focusing on cancer, promising nanoprototypes have been designed to overcome the lack of specificity of conventional chemotherapeutic agents, as well as for early detection of precancerous and malignant lesions. However, several obstacles, including difficulty in achieving the optimal combination of physicochemical parameters for tumor targeting, evading particle clearance mechanisms, and controlling drug release, prevent the translation of nanomedicines into therapy. In spite of this, recent efforts have been focused on developing functionalized nanoparticles for delivery of therapeutic agents to specific molecular targets overexpressed on different cancer cells. In particular, the combination of targeted and controlled-release polymer nanotechnologies has resulted in a new programmable nanotherapeutic formulation of docetaxel, namely BIND-014, which recently entered Phase II clinical testing for patients with solid tumors."
According to the news reporters, the research concluded: "BIND-014 has been developed to overcome the limitations facing delivery of nanoparticles to many neoplasms, and represents a validated example of targeted nanosystems with the optimal biophysicochemical properties needed for successful tumor eradication."
For more information on this research see: Targeted therapy using nanotechnology: focus on cancer. International Journal of Nanomedicine, 2014;9():467-483. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Biotechnology).
Our news correspondents report that additional information may be obtained by contacting V. Sanna, University of Sassari, Dept. of Chem & Pharm, Lab Nanomed, I-07100 Sassari, Italy. Additional authors for this research include N. Pala and M. Sechi.
Keywords for this news article include: Biotechnology, Italy, Europe, Sassari, Oncology, Nanoparticle, Nanotechnology, Cancer Gene Therapy, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC